Hepion Pharmaceuticals, Inc. (HEPA)

1.3100 -0.0400 (-2.96%) 收市：04:00PM EDT

Hepion Pharmaceuticals, Inc.

399 Thornall Street
First Floor
Edison, NJ 08837
United States
732 902 4000
https://www.hepionpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 22

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. John T. Cavan	Interim CEO & CFO	495.33k	無	1958
Sharen Pyatetskaya	Director of Investor Relations	無	無	無
Dr. John Z. Sullivan-Bolyai	Part-Time Consultant	無	無	1948
Dr. Stephen A. Harrison FACP, M.D.	Scientific Advisory Board Chair & Consultant Medical Director	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

公司管治

截至 無 止，Hepion Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。